New hope for endometriosis pain: phase 3 drug trial launches

NCT ID NCT07318688

First seen Jan 10, 2026 · Last updated Apr 28, 2026 · Updated 16 times

Summary

This study tests a new drug called HMI-115 for women with moderate to severe pain from endometriosis. About 540 women aged 18-49 with surgically confirmed endometriosis will receive either the drug or a placebo for 24 weeks, with a 28-week follow-up. The goal is to see if the drug reduces menstrual and pelvic pain better than a placebo.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Nanjing Women and children's healthcare hospital

    Nanning, Jiangsu, China

    Contact

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, 100703, China

    Contact

  • Second Affiliated Hospital of Soochow University

    Suzhu, Jiangsu, China

  • The International Peace Maternity and Child Health Hospital of the China Welfare Institute

    Shanghai, Shanghai Municipality, China

    Contact

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, China

    Contact

Conditions

Explore the condition pages connected to this study.